Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Pidnarulex and Trastuzumab Deruxtecan for HER2 Positive Advanced Breast Cancer

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors

Purpose: To study the safety, effects (good and bad), anti-cancer activity, and best dose of pidnarulex combined with trastuzumab deruxtecan (Enhertu®, T-DXd).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose tumors express HER2 including HER2 low, or HER2 ultralow, who have received at least 1 prior line of chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-5461 (Pidnarulex), by IV, every 21 days</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV, 1 time</li> <li class="seamTextUnorderedListItem">Follow-up visits, 30 days after treatment ends, and for then for 3 years</li></ul>

What's being studied?


How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07137416' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
1

Pidnarulex and Trastuzumab Deruxtecan for HER2 Positive Advanced Breast Cancer

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors
Icon

Nearest Location from 94107:
2693 miles
Dana-Farber - Harvard Cancer Center LAO
Boston, MA

Icon

Visits:
2 visits every 3 weeks

Icon

ClinicalTrials.gov: NCT07137416

Icon

Phase I

HELP GUIDE